Ranbaxy enters into licensing pact with EPIRUS Switzerland

Ranbaxy Laboratories today inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a

RELATED ARTICLES

biosimilar version of Infliximab prescribed to treat rheumatoid arthritis (RA).

EPIRUS Switzerland GmbH is a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals, Inc.

The product will be introduced in India and other Emerging Markets, the company said in a statement.

At present, there is no biosimilar of Infliximab approved in India, it said.

Under the terms of the agreement, EPIRUS will develop and supply the product; and upon regulatory approval, Ranbaxy will market the same in India and other emerging markets.

Commenting on the partnership, Sanjeev I Dani, Executive Vice President & Head, Global Strategy, Ranbaxy, said, "We will utilise our strong front-end capabilities in making this product available in India and other parts of the world."

Amit Munshi, President and CEO of EPIRUS said: "We are very pleased to work with Ranbaxy to register and commercialise this important medicine. Ranbaxy has the right focus and infrastructure in these markets to effectively bring this product to the market."

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Media obsession with his layoff smacks of lack of focus

    Pretty much like his abrupt vanishing act had done 50-odd days ago, Congress vice president Rahul Gandhi’s return on Thursday from a long and myster

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Varun Dutt

<b>Riskfactor</b>: Oblivious to reality

The hostile media effect, originally deemed the hostile media phenomenon, ...

Zehra Naqvi

Sensual wordplay

The student of literature looks for form and structure. The ...

Bubbles Sabharwal

The bitter cold heart of life

Life has a heart just as we do. Most times ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture